The development and utility of a clinical algorithm to predict early HIV-1 infection

Journal of Acquired Immune Deficiency Syndromes

Volumn 40, Issue 4, 2005, Pages 472-478

  Sharghi, Neda ^a   Bosch, Ronald J ^b   Mayer, Kenneth ^a,c,e   Essex, Max ^a,d   Seage III, George R ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^c Harvard AIDS Institute   (United States)

^d BROWN UNIVERSITY   (United States)

^e Research Department   (United States)

Author keywords

Clinical factors; Early and acute HIV 1 infection; HIV Network for Prevention Trials (HIVNET); Microbicide trials; Vaccine preparedness study; Vaccine trials

Indexed keywords

ADULT; AGED; ALGORITHM; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE TRANSMISSION; FEMALE; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PREDICTION; PRIORITY JOURNAL; SELF REPORT;

ADOLESCENT; ADULT; ALGORITHMS; CHLAMYDIA INFECTIONS; FEMALE; FEVER; FORECASTING; GONORRHEA; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; MALE; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK FACTORS; SENSITIVITY AND SPECIFICITY; STATISTICS; SWEATING;

EID: 27944496016     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000164246.49098.47     Document Type: Article

References (35)

1. Hecht FM, Busch MP, Rawal B, et al. Use of laboratory tests and clinical symptoms for identification of primary HIV infection. AIDS. 2002;16:1119-1129.
2. Daar ES, Moudgil T, Meyer RD, et al. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N Engl J Med. 1991;324:961-964.
3. Janssen RS, Satten GA, Stramer SL, et al. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA. 1998;280:42-48.
4. Kahn JO, Walker BD. Acute human immunodeficiency virus type 1 infection. N Engl J Med. 1998;339:33-39.
5. Lindback S, Brostrom C, Karlsson A, et al. Does symptomatic primary HIV-1 infection accelerate progression to CDC stage IV disease, CD4 count below 200 X 10(6)/1, AIDS, and death from AIDS? BMJ. 1994;309:1535-1537.
6. Keet IP, Krijnen P, Koot M, et al. Predictors of rapid progression to AIDS in HIV-1 seroconverters. AIDS. 1993;7:51-57.
7. Dorrucci M, Rezza G, Vlahov D, et al. Clinical characteristics and prognostic value of acute retroviral syndrome among injecting drug users. Italian Seroconversion Study. AIDS. 1995;9:597-604.
8. Vanhems P, Lambert J, Cooper DA, et al. Severity and prognosis of acute human immunodeficiency virus type 1 illness: a dose-response relationship. Clin Infect Dis. 1998;26:323-329.
9. Malhotra U, Berrey MM, Huang Y, et al. Effect of combination antiretroviral therapy on T-cell immunity in acute human immunodeficiency virus type 1 infection. J Infect Dis. 2000;181:121-131.
10. Rosenberg ES, Altfeld M, Poon SH, et al. Immune control of HIV-1 after early treatment of acute infection. Nature. 2000;407:523-526.
11. Pilcher CD, McPherson JT, Leone PA, et al. Real-time, universal screening for acute HIV infection in a routine HIV counseling and testing population. JAMA. 2002;288:216-221.
12. Klausner RD, Fauci AS, Corey L, et al. Medicine: the need for a global HIV vaccine enterprise [see comment]. Science. 2003;300:2036-2039.
13. Bollinger RC, Brookmeyer RS, Mehendale SM, et al. Risk factors and clinical presentation of acute primary HIV infection in India. JAMA. 1997;278:2085-2089.
14. Taiwo BO, Hicks CB. Primary human immunodeficiency virus. South Med J. 2002;95:1312-1317.
15. Kinloch-de Loes S, de Saussure P, Saurat JH, et al. Symptomatic primary infection due to human immunodeficiency virus type 1: review of 31 cases. Clin Infect Dis. 1993;17:59-65.
16. Sinicco A, Palestro G, Caramello P, et al. Acute HIV-1 infection: clinical and biological study of 12 patients. J Acquir Immune Defic Syndr. 1990;3:260-265.
17. Daar ES, Bai J, Hausner MA, et al. Acute HIV syndrome after discontinuation of antiretroviral therapy in a patient treated before seroconversion. Ann Intern Med. 1998;128:827-829.
18. Tindall B, Barker S, Donovan B, et al. Characterization of the acute clinical illness associated with human immunodeficiency virus infection. Arch Intern Med. 1988;148:945-949.
19. Schacker T, Collier AC, Hughes J, et al. Clinical and epidemiologic features of primary HIV infection. Ann Intern Med. 1996;125:257-264.
20. Pedersen C, Lindhardt BO, Jensen BL, et al. Clinical course of primary HIV infection: consequences for subsequent course of infection. BMJ. 1989;299:154-157.
21. Quinn TC. Acute primary HIV infection. JAMA. 1997;278:58-62.
22. Rosenberg ES, Caliendo AM, Walker BD. Acute HIV infection among patients tested for mononucleosis. N Engl J Med. 1999;340:969.
23. Walensky RP, Rosenberg ES, Ferraro MJ, et al. Investigation of primary human immunodeficiency virus infection in patients who test positive for heterophile antibody. Clin Infect Dis. 2001;33:570-572.
24. Vidrih JA, Walensky RP, Sax PE, et al. Positive Epstein-Barr virus heterophile antibody tests in patients with primary human immunodeficiency virus infection. Am J Med. 2001;111:192-194.
25. Koblin BA, Heagerty P, Sheon A, et al. Readiness of high-risk populations in the HIV Network for Prevention Trials to participate in HIV vaccine efficacy trials in the United States. AIDS. 1998;12:785-793.
26. Seage GR 3rd, Holte SE, Metzger D, et al. Are US populations appropriate for trials of human immunodeficiency virus vaccine? The HIVNET Vaccine Preparedness Study. Am J Epidemiol. 2001;153:619-627.
27. National Institute of Allergy and Infectious Diseases, NIH, Department of Health and Human Services. Vaccine Preparedness Study, Uninfected Participant Cohort. FHCRC-HIVNET Statistical Center Version. March 2000.
28. Diggle PJ, Heagerty P, Liang K-Y, Zeger S. Analysis of Longitudinal Data, 2nd ed. New York: Oxford University Press; 2002.
29. Pilcher CD, Price MA, Hoffman IF, et al. Frequent detection of acute primary HIV infection in men in Malawi. AIDS. 2004;18:517-524.
30. Pilcher CD, Eron JJ Jr, Galvin S, et al. Acute HIV revisited: new opportunities for treatment and prevention. J Clin Invest. 2004;113:937-945.
31. Anonymous. Advancing HIV prevention: new strategies for a changing epidemic - United States, 2003. MMWR Morb Mortal Wkly Rep. 2003;52:329-332.
32. Voelker R. Detecting acute HIV infections feasible, North Carolina program demonstrates. JAMA. 2003;289:2633-2634.
33. Lavreys L, Thompson ML, Martin HL Jr, et al. Primary human immunodeficiency virus type 1 infection: clinical manifestations among women in Mombasa, Kenya. Clin Infect Dis. 2000;30:486-490.
34. Celum CL, Buchbinder SP, Donnell D, et al. Early human immunodeficiency virus (HIV) infection in the HIV Network for Prevention Trials Vaccine Preparedness Cohort: risk behaviors, symptoms, and early plasma and genital tract virus load. J Infect Dis. 2001;183:23-35.
35. Vanhems P, Routy JP, Hirschel B, et al. Clinical features of acute retroviral syndrome differ by route of infection but not by gender and age. J Acquir Immune Defic Syndr. 2002;31:318-321.